PFM Health Sciences, LP
About PFM Health Sciences, LP’s 13F portfolio
PFM Health Sciences, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , PFM Health Sciences, LP reported $1.2B across 96 US-listed positions (). Its largest position is ASCENDIS PHARMA A/S (ASND) at 5.4% of the reported book, and its ten biggest holdings make up 34% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: ASND ASCENDIS PHARMA A/S | $255.96 −5.32% | 5.4% | 233K | $62.2M |
| 2 | NASDAQ: AXSM AXSOME THERAPEUTICS INC. | $135.68 +1.25% | 4.7% | 220K | $53.8M |
| 3 | NYSE: LLY ELI LILLY & CO | $1,351.12 −2.29% | 4.1% | 39K | $47.1M |
| 4 | NASDAQ: JAZZ JAZZ PHARMACEUTICALS PLC | $236.45 −4.57% | 3.4% | 161K | $38.7M |
| 5 | NYSE: HUM HUMANA INC | $380.00 −1.50% | 3.3% | 94K | $37.5M |
| 6 | NYSE: UNH UNITEDHEALTH GROUP INC | $330.48 −5.55% | 3.2% | 88K | $36.7M |
| 7 | NASDAQ: NBIX NEUROCRINE BIOSCIENCES INC | $156.59 −3.85% | 3.1% | 213K | $36.0M |
| 8 | NASDAQ: INBX INHIBRX BIOSCIENCES INC | $74.33 +7.63% | 2.5% | 308K | $29.2M |
| 9 | NASDAQ: UTHR UNITED THERAPEUTICS CORP DEL | $559.10 −3.16% | 2.4% | 50K | $27.1M |
| 10 | NASDAQ: RVMD REVOLUTION MEDICINES INC | $159.43 −0.24% | 2.3% | 143K | $26.8M |
| 11 | NASDAQ: ICLR ICON PUB LTD CO | $190.36 −2.46% | 2.1% | 136K | $23.7M |
| 12 | NYSE: THC TENET HEALTHCARE CORP | $263.59 −2.86% | 2.1% | 127K | $23.7M |
| 13 | NYSE: EW EDWARDS LIFESCIENCES CORP | $103.88 −1.28% | 2.0% | 250K | $22.7M |
| 14 | NYSE: WAT WATERS CORP | $456.48 −2.06% | 1.9% | 60K | $22.4M |
| 15 | NYSE: PEN PENUMBRA INC | $320.01 −0.18% | 1.7% | 60K | $19.0M |
| 16 | NASDAQ: BBIO BRIDGEBIO PHARMA INC | $78.18 +0.22% | 1.6% | 253K | $18.9M |
| 17 | NYSE: SYK STRYKER CORPORATION | $313.08 −1.59% | 1.5% | 57K | $17.8M |
| 18 | NYSE: MTD METTLER TOLEDO INTERNATIONAL | $1,705.66 −1.82% | 1.5% | 13K | $17.0M |
| 19 | NASDAQ: INDV INDIVIOR PHARMACEUTICALS INC | $26.74 −5.21% | 1.4% | 401K | $16.5M |
| 20 | NYSE: MRK MERCK & CO INC | $132.81 −3.61% | 1.4% | 127K | $16.3M |
| 21 | NASDAQ: CYTK CYTOKINETICS INC | $51.46 +0.27% | 1.4% | 192K | $16.3M |
| 22 | NASDAQ: LNTH LANTHEUS HLDGS INC | $102.10 +0.10% | 1.4% | 146K | $16.2M |
| 23 | NYSE: CNC CENTENE CORP DEL | $65.58 −2.77% | 1.4% | 249K | $16.0M |
| 24 | NASDAQ: COO COOPER COS INC | $60.33 −0.69% | 1.4% | 221K | $15.8M |
| 25 | NASDAQ: MDGL MADRIGAL PHARMACEUTICALS INC | $396.74 −0.34% | 1.4% | 29K | $15.7M |
Showing 1–25 of 96 positions on this page reported in this 13F.
- Healthcare98%
- NewASNDASCENDIS PHARMA A/S—$62.2M
- NewHUMHUMANA INC—$37.5M
- AddedUNHUNITEDHEALTH GROUP INC+52.1%$36.7M
- AddedINBXINHIBRX BIOSCIENCES INC+1.0%$29.2M
- AddedUTHRUNITED THERAPEUTICS CORP DEL+25.6%$27.1M
- AddedRVMDREVOLUTION MEDICINES INC+1.7%$26.8M
- AddedICLRICON PUB LTD CO+137%$23.7M
- AddedWATWATERS CORP+50.5%$22.4M
- AddedSYKSTRYKER CORPORATION+158%$17.8M
- NewMTDMETTLER TOLEDO INTERNATIONAL—$17.0M
- ReducedAXSMAXSOME THERAPEUTICS INC.−16.9%$53.8M
- ReducedLLYELI LILLY & CO−40.3%$47.1M
- ReducedJAZZJAZZ PHARMACEUTICALS PLC−9.8%$38.7M
- ReducedNBIXNEUROCRINE BIOSCIENCES INC−1.1%$36.0M
- ReducedTHCTENET HEALTHCARE CORP−68.2%$23.7M
- ReducedEWEDWARDS LIFESCIENCES CORP−1.6%$22.7M
- ReducedPENPENUMBRA INC−56.9%$19.0M
- ReducedBBIOBRIDGEBIO PHARMA INC−1.7%$18.9M
- ReducedINDVINDIVIOR PHARMACEUTICALS INC−30.2%$16.5M
- ReducedCNCCENTENE CORP DEL−5.5%$16.0M
Reading PFM Health Sciences, LP’s 13F portfolio
PFM Health Sciences, LP’s $1.2B 13F book is spread across 96 reported positions and is moderately diversified, the ten largest names accounting for 34%. There are meaningful positions at the top alongside a long tail of smaller holdings. Its five largest positions are ASND, AXSM, LLY, JAZZ and HUM, led by ASCENDIS PHARMA A/S (ASND) at 5.4% of the portfolio. The heaviest sector exposure is Healthcare (98%).
What PFM Health Sciences, LP changed last quarter
Between 2026-03-31 and Q2 2026, PFM Health Sciences, LP was roughly balanced between buying and selling: it opened 33 new positions and added to 22 more, while trimming 41 and closing 14 outright. Against a 96-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ASCENDIS PHARMA A/S (ASND), and its biggest reduction was AXSOME THERAPEUTICS INC. (AXSM).
What a 13F does and doesn’t reveal
A 13F captures only PFM Health Sciences, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names PFM Health Sciences, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. PFM Health Sciences, LP's profile on this page is built directly from those filings.
How current is the 13F data on PFM Health Sciences, LP's page?
It reflects PFM Health Sciences, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When PFM Health Sciences, LP files its next quarterly report, this page refreshes automatically.
Can I see PFM Health Sciences, LP's complete list of holdings?
This page highlights PFM Health Sciences, LP's largest positions rather than all 96 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under PFM Health Sciences, LP's filings.
Does a 13F show everything PFM Health Sciences, LP owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of PFM Health Sciences, LP's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why PFM Health Sciences, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

